Science Matters: Insights Into Gut-Brain Signaling Raise Hopes For Treating Neurological Disorders
New research offers mechanistic proof of signaling between gut and brain in Parkinson’s disease, showing that introducing an altered microbiome from PD patients into a mouse model can recreate the motor symptoms of the disease.
You may also be interested in...
Finance Watch: VC Mega-Deals Launch Biopharma Firms With New Takes On CV, Genetic Diseases
Anthos premiers with $250m from Blackstone and cardiovascular disease assets and expertise from Novartis, while Maze brings in $191m for drugs that target gene modifiers. In public company financings, Sage raises $575m ahead of Zulresso approval decision.
Diagnostics In 2016: From Alere To Zika
No significant trends emerged in diagnostics M&A or financing this past year, which did see the introduction of several government-funded initiatives, elements of which will bolster diagnostics innovation. As in other sectors of health care, the biggest question is how the incoming Trump administration could change US regulatory and funding policies.
Science Matters: Innovative Strategy Identifies New Antibiotic Class From The Microbiome
New research lays out both method and proof of principle for a strategy that combines bioinformatics and synthetic chemistry to enable more expansive development of antibiotics and other drugs derived from natural products.